Skip to content

Priming stimulation as an enhancement of low-frequency repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of tinnitus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN03638520
Enrollment
32
Registered
2007-08-23
Start date
2003-03-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic tinnitus Ear, Nose and Throat Chronic tinnitus

Interventions

Experimental intervention: Low frequency rTMS over the left auditory cortex with priming stimulation: 6Hz (90% motor threshold, 960 stimuli) followed by low frequency rTMS (110% motor threshold, 1Hz,

Sponsors

Regensburg District Clinic (Bezirksklinikum Regensburg) (Germany)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Female and male in- and outpatients 2. Age 18-70 years 3. Diagnosis of subjective chronic tinnitus 4. Duration of tinnitus more than 6 months

Exclusion criteria

Exclusion criteria: 1. Patients with conductive hearing loss of more than 15dB 2. Objective tinnitus 3. Treatable otologic disorder 4. Involvement in other treatments for tinnitus at the same time 5. Clinically relevant psychiatric comorbidity 6. Clinically relevant unstable internal or neurological comorbidity 7. History of or evidence of significant brain malformation or neoplasm, head injury 8. Cerebral vascular events 9. Neurodegenerative disorder affecting the brain or prior brain surgery; 10. Factors militating against the use of TMS (e.g. cardiac pace makers or other metal implants) 11. Pregnancy

Design outcomes

Primary

MeasureTime frame
Change in tinnitus severity according to the Tinnitus Questionnaire of Goebel and Hiller (baseline vs day 12).

Secondary

MeasureTime frame
Reduction of tinnitus severity as measured by the Tinnitus Questionnaire of Goebel and Hiller (TQ; THI) during the follow-up period (screening versus baseline versus days 18, 59, 90).

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026